Pro Share Advisors LLC Chinook Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$18.66 - $38.58 $194,829 - $402,813	10,441 Added 99.14%	20,973 $805,000
Q1 2023 May 11, 2023	SELL	$21.53 - $26.8 $27,536 - $34,277	-1,279 Reduced 10.83%	10,532 $243,000
Q4 2022 Feb 02, 2023	BUY	$18.63 - $27.35 $19,058 - $27,979	1,023 Added 9.48%	11,811 $309,000
Q3 2022 Nov 04, 2022	BUY	$17.51 - $23.37 $188,897 - $252,115	10,788 New	10,788 $211,000
Q2 2022 Aug 01, 2022	SELL	$12.59 - $18.8 $164,186 - $245,170	-13,041 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$12.02 - $16.69 $35,338 - $49,068	-2,940 Reduced 18.4%	13,041 $214,000
Q4 2021 Feb 08, 2022	BUY	$10.69 - $16.83 $23,186 - $36,504	2,169 Added 15.7%	15,981 $260,000
Q3 2021 Nov 12, 2021	SELL	$11.5 - $14.86 $27,174 - $35,114	-2,363 Reduced 14.61%	13,812 $176,000
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $219,980 - $307,001	16,175 New	16,175 $228,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Pro Share Advisors LLC with notifications on news.